Dr. James R. Gavin III Appointed as Senior Medical

New Post Public Reply Private Reply Replies (0) Message Board
testuser
Dr. James R. Gavin III Appointed as Senior Medical Consultant for ALR Technologies

RICHMOND, VA--(Marketwired - Apr 10, 2013) - ALR Technologies ( OTCBB : ALRT ) today announced that Dr. James R. Gavin III, MD, PhD, one of the world's leading experts on diabetes care, has been appointed Senior Medical Consultant for the company. As Senior Medical Consultant, Dr. Gavin will provide strategic advice on clinical aspects of the company's operations with a particular focus on the company's Health-e-Connect Diabetes Management Program. That program allows for the remote monitoring of patients' blood glucose levels combined with a robust care facilitation capability. Dr. Gavin will also provide strategic input on working with health care payers and providers based on his extensive network of medical colleagues. As one of the world's leading diabetes clinicians, Dr. Gavin's expertise will be invaluable in guiding the commercial launch of the ALRT Program. ALRT's Health-e-Connect Diabetes Management Program focuses on the right level of monitoring combined with helpful and constructive communication with patients, providers and caregivers. Dr. Gavin has devoted his career to this type of front line diabetes care. 

"I am truly humbled that a clinician of Dr. Gavin's stature would sign on to help ALR Technologies," said Sidney Chan, Chief Executive Officer of ALR Technologies. "Dr. Gavin's decision gives me great confidence that our Health-e-Connect Diabetes Management Program will create a new paradigm in diabetes care and foster a system of care that will allow more patients to meet their goals."

"In recent years, I have been increasingly alarmed that the status quo for diabetes care is not working," said Dr. Gavin. "We need to look for new models and new technologies that will bend the current trends for diabetes care in a more promising direction. The ALRT model of patient-centered remote monitoring combined with helpful communication and care facilitation for the patient is one of those transformative models that we must pursue. I am eager to be part of this exciting new model for diabetes care."

Dr. Gavin currently serves as CEO and Chief Medical Officer of Healing Our Village, Inc, Clinical Professor of Medicine at Emory University School of Medicine, and Clinical Professor of Medicine at Indiana University School of Medicine. Dr. Gavin is a former president of the American Diabetes Association. Prior to this, he was president of the Morehouse School of Medicine in Atlanta from 2002-2004. He served as senior scientific officer at the Howard Hughes Medical Institute (HHMI) from 1991 to 2002 and as director of the HHMI-National Institutes of Health Research Scholars Program from 2000 to 2002. Before joining the senior staff of HHMI, Dr. Gavin was professor and chief of the Diabetes Section, acting chief of the Section on Endocrinology, Metabolism, and Hypertension, and William K. Warren Professor for Diabetes Studies at the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. He previously served as an associate professor of medicine at Washington University School of Medicine in St. Louis, Missouri. Dr. Gavin served as a lieutenant commander in the US Public Health Service from 1971 to 1973 and continues to serve as a reserve officer.

About ALR Technologies
ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with chronic diseases. ALRT has developed the FDA-cleared Health-e-Connect system which uploads the data from blood glucose meters onto a secure website where clinicians and others can better monitor and coordinate the care of these patients. The platform will be expanded to cover patients with other chronic diseases. More information on ALR Technologies and its products can be found at http://www.alrt.com .

This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate", "expect", "anticipate", "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company's quarterly filings with the Securities Exchange Commission.

Contact:
Bill Smith
bill.smith@alrt.com
203-762-1073

Investors-Hangout-Stock-Message-Boards-thumbnail-2015.png

test123 kjk
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Castle Biosciences Unveils Key Data on TissueCypher at ACG

Updated Category News Views 289

New Insights from Castle Biosciences at Annual Meeting Castle Biosciences, Inc. (NASDAQ: CSTL) recently highlighted groundbreaking research at a prestigious conference, showcasing its innovative TissueCypher Barrett's Esophagus test. This test provides critical risk insights that go beyond traditional pathology, influencing clinical management for early intervention in...

Continue Reading
Ben Foster Takes Charge as Chair of Rural Broadband Board

Updated Category News Views 97

Announcement of Ben Foster's Chair Appointment In a significant development for rural connectivity, Ben Foster, President and CEO of Twin Valley, has been appointed as the chair of the National Rural Broadband Association (NTCA). As a leader of Kansas' largest independently owned broadband and communications company, Foster's new role marks an important step for improving...

Continue Reading
Interoil's Bond Payment Restructuring Proposal Explained

Updated Category News Views 260

Interoil's Bond Payment Restructuring Proposal Interoil Exploration and Production ASA (the "Company") has initiated a process with Nordic Trustee AS to gather bondholders for a written resolution. This action concerns the senior secured callable bonds identified by ISIN NO 001 0729908 (the "Bonds"). Purpose of the Written Resolution The primary goal of this resolution is...

Continue Reading
DoubleLine Income Solutions Fund Announces Upcoming Distribution

Updated Category News Views 103

DoubleLine Income Solutions Fund Declares Distribution The DoubleLine Income Solutions Fund (the "Fund"), recognized under the symbol DSL on the New York Stock Exchange, has announced a forthcoming distribution of $0.11 per share. It’s important for investors to stay informed about the timing and details of these distributions. Distribution Overview This distribution...

Continue Reading
Interoil Reports October Production Growth and Updates

Updated Category News Views 118

Key Production Metrics and Overview Interoil Exploration and Production ASA has recently released its production metrics, showcasing a notable improvement in operational output for October. The total operated production in October averaged 2,239 barrels of oil equivalent per day (boepd), representing an increase of 157 boepd from the previous month. This positive trend...

Continue Reading